Dyne's Zeleciment Basivarsen Shows Sustained Gains in DM1 Trial at One Year

Dyne Therapeutics Inc. (NASDAQ:DYN) is one of the best hot stocks to invest in. On October 7, Dyne Therapeutics announced additional one-year clinical data from the ongoing Phase 1/2 ACHIEVE trial of zeleciment basivarsen (z-basivarsen), formerly known as DYNE-101, for patients with Myotonic Dystrophy Type 1/DM1.

The data was released at the 30th Annual International Congress of the World Muscle Society/WMS in Vienna, Austria, and demonstrated robust and clinically meaningful improvements in function and strength at the selected registrational dose. The data also supported the clinical meaningfulness of the functional improvements to patients. Meaningful and sustained improvements from baseline were observed in the Myotonic Dystrophy Health Index/MDHI patient-reported outcome measure, including in the subscales for central nervous system manifestations.

New data showed improvements in other MDHI subscales, including mobility, ability to do activities, and upper extremity function. Furthermore, new data from both the Patient Global Impression of Change (PGI-C) and Clinician Global Impression of Change (CGI-C) scales indicated improvements from baseline in overall disease burden, as reported by both patients and physicians.

Dyne Therapeutics Inc. (NASDAQ:DYN) is a clinical-stage neuromuscular disease company that discovers and develops therapeutics for neuromuscular diseases in the US.

While we acknowledge the potential of DYN as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.